2. Metabolic Enzyme/Protease
  3. Renin
  4. CP 71362

CP 71362 is a renin inhibitor, a highly potent substrate-analog transition state mimic with antihypertensive properties. CP 71362 exhibits significant inhibitory activity against plasma renin from rats, dogs, and humans (IC50 values are 3 nM, 0.0033 nM, and 20 nM, respectively). CP 71362 reduces the mean arterial pressure of anesthetized and conscious sodium-depleted animals in a dose-dependent manner, and has pharmacokinetic characteristics of rapid elimination and short duration of action. CP 71362 can be used in research related to hypertension and congestive heart failure.

For research use only. We do not sell to patients.

CP 71362

CP 71362 Chemical Structure

CAS No. : 112227-15-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CP 71362 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CP 71362 is a renin inhibitor, a highly potent substrate-analog transition state mimic with antihypertensive properties. CP 71362 exhibits significant inhibitory activity against plasma renin from rats, dogs, and humans (IC50 values are 3 nM, 0.0033 nM, and 20 nM, respectively). CP 71362 reduces the mean arterial pressure of anesthetized and conscious sodium-depleted animals in a dose-dependent manner, and has pharmacokinetic characteristics of rapid elimination and short duration of action. CP 71362 can be used in research related to hypertension and congestive heart failure[1][2].

In Vitro

CP-71,362 exhibits high specificity for renin, with a potency 6 orders of magnitude lower against bovine spleen cathepsin D (IC50=1.3×10-6 M), and shows no inhibitory activity against rabbit lung ACE at concentrations up to 1×10-3 M[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CP 71362 Related Antibodies
In Vivo

CP 71362 (1.1-4.5 μg/kg/min; i.v.; continuous infusion) produces dose-dependent reductions in mean arterial pressure in anesthetized, sodium-depleted dogs, with an ED50 infusion rate of 1.1 μg/kg/min and a maximal 35 mmHg pressure decrease at 3.7 μg/kg/min[1].
CP 71362 (9.7-30 μg/kg/min; i.v.; continuous infusion) reduces mean arterial pressure in conscious, sodium-depleted Sprague-Dawley rats, with an ED50 infusion rate of 9.7 μg/kg/min and a 30-40 mmHg pressure decrease at 30 μg/kg/min[1].
CP 71362 (0.1-3 mg/kg; i.v. bolus) produces dose-dependent mean arterial pressure lowering in conscious, sodium-depleted Cavia porcellus, with the 1.0 and 3.0 mg/kg bolus doses maintaining significant effects for at least 2 hours[2].
CP 71362 (1.06-100 μg/kg/min; i.v. infusion; 10-30 minutes) produces dose-dependent, reversible mean arterial pressure lowering in anesthetized, sodium-depleted dogs, with an ED50 of 1.06 μg/kg/min, and completely suppresses plasma renin activity at the ED50 dose[2].
CP 71362 (4.3-43.3 μg/kg/min; i.v. infusion; 30 minutes) produces rapid, dose-dependent, fully reversible mean arterial pressure lowering in conscious, sodium-depleted SHR, with an ED50 of 5 μg/kg/min[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: (anesthetized, sodium-depleted)[1]
Dosage: 1.1 μg/kg/min (ED50 infusion rate); 3.7 ± 0.4 μg/kg/min; 4.5 ± 0.7 μg/kg/min
Administration: i.v.; continuous infusion
Result: Reduced mean arterial pressure by 35 mmHg (from 119 mmHg to 84 mmHg, n=5).
Achieved an ED50 infusion rate of 1.1 μg/kg/min for half-maximal decrease in renin-dependent blood pressure.
Produced near-maximal effects on mean arterial pressure at 4.5 ± 0.7 μg/kg/min (~4× the ED50 dose).
Returned mean arterial pressure to pre-infusion levels within 30-60 minutes after cessation of infusion.
Animal Model: Sprague-Dawley (conscious, sodium-depleted)[1]
Dosage: 9.7 μg/kg/min (ED50 infusion rate); 30 μg/kg/min
Administration: i.v.; continuous infusion
Result: Reduced mean arterial pressure by 30-40 mmHg at 30 μg/kg/min.
Achieved an ED50 infusion rate of 9.7 μg/kg/min for half-maximal fall in renin-dependent blood pressure.
Animal Model: Charles River (300-350g; sodium-depleted, renin-dependent hypertension model)[2]
Dosage: 0.1 mg/kg; 1.0 mg/kg; 3.0 mg/kg
Administration: i.v. bolus
Result: Caused a maximum mean arterial pressure decrease of 32 ± 5 mmHg, with significant lowering sustained for 60 minutes at 0.1 mg/kg.
Caused a maximum mean arterial pressure decrease of 36 ± 3 mmHg, with significant lowering sustained for at least 120 minutes at 1.0 mg/kg.
Caused a maximum mean arterial pressure decrease of 38 ± 1 mmHg, with significant lowering sustained for at least 120 minutes at 3.0 mg/kg.
Animal Model: Mongrel (10-15 kg; sodium-depleted, renin-dependent hypertension model)[2]
Dosage: 1.06 µg/kg/min; 4.52 µg/kg/min; 5.0 µg/kg/min; 10.0 µg/kg/min; 20.0 µg/kg/min; 50.0 µg/kg/min; 100.0 µg/kg/min
Administration: i.v. infusion; 30 minutes (most doses); 10 minutes (4.52 µg/kg/min)
Result: Caused dose-dependent lowering of mean arterial pressure, with a maximum decrease of ~50 mmHg at 10.0 µg/kg/min.
Achieved an ED50 of 1.06 µg/kg/min for mean arterial pressure lowering.
Reduced mean arterial pressure from ~115 mmHg to 80 mmHg at 4.52 µg/kg/min, with pressure returning to pre-infusion levels approximately 1 hour after infusion termination.
Reduced plasma renin activity from 23.8 ± 2.5 to 0.04 ± 0.01 ng AngI/mL/hr (p < 0.01) at 1.11 µg/kg/min (ED50 dose).
Animal Model: Spontaneously Hypertensive Rats (SHR) (Charles River, 275-300 g; sodium-depleted, renin-dependent hypertension model)[2]
Dosage: 4.3 µg/kg/min; 10.8 µg/kg/min; 43.3 µg/kg/min
Administration: i.v. infusion; 30 minutes
Result: Caused dose-dependent mean arterial pressure lowering, with a maximum decrease of 43 mmHg at 43.3 µg/kg/min.
Achieved an ED50 of 5 µg/kg/min for mean arterial pressure lowering.
Reached a stable nadir within 10-20 minutes of starting infusion, with pressure returning to baseline within 5 minutes of stopping infusion.
Molecular Weight

945.20

Formula

C51H76N8O9
CAS No.
SMILES

O=C([C@@H](NC(OC(C)(C)C)=O)CC1=CC=CC=C1)N[C@H](C(N[C@@]([H])(CC2CCCCC2)[C@@H](O)C[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC3=CC=CC=C3)=O)CCCCN)=O)CC(C)C)=O)CC4=CNC=N4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CP 71362 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CP 71362112227-15-3CP71362CP-71362Reninrat plasma reninrabbit lung ACEsubstrate analog transition state mimicbovine spleen cathepsin Drenin angiotensin systemcongestive heart failurehuman plasma reninrenin inhibitorhypertensiondog plasma reninInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CP 71362
Cat. No.:
HY-182301
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.